Free shipping on all orders over $ 500

Mitazalimab

Cat. No. M24893
Mitazalimab Structure
Synonym:

ADC-1013; JNJ-64457107

Size Price Availability Quantity
100ug USD 460  USD460 In stock
1mg USD 1360  USD1360 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Chemical Information
CAS Number 2055640-86-1
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Victor Moreno, et al. Invest New Drugs. A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

[2] Adnan Deronic, et al. Cancer Immunol Immunother. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

[3] Sandra M M Irenaeus, et al. Int J Cancer. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

[4] Roxana S Dronca, et al. Clin Cancer Res. Immunomodulatory antibody therapy of cancer: the closer, the better

[5] Sara M Mangsbo, et al. Clin Cancer Res. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity

Related TNF Receptor Products
Chilob7/4

Chilob7/4 is a chimeric agonist anti-CD40 IgG1 antibody that can be used for tumor-related studies.

VIB4920

VIB4920 is a fusion protein that binds to CD40L on activated T cells and blocks the interaction of CD40L with CD40-expressing B cells and other possible binding substrates.

ABBV-428

ABBV-428 is a bispecific antibody targeting CD40/Mesothelin and can be used in studies related to solid tumors.

TNF-α (31-45), human

TNF-α (31-45), human is a potent NF-kB pathway activator.

LEESGGGLVQPGGSMK

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab.

  Catalog
Abmole Inhibitor Catalog




Keywords: Mitazalimab, ADC-1013; JNJ-64457107 supplier, TNF Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.